Page last updated: 2024-08-24

triazoles and exenatide

triazoles has been researched along with exenatide in 117 studies

Research

Studies (117)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's37 (31.62)29.6817
2010's80 (68.38)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Drucker, DJ; Nauck, MA1
Campbell, KM; Taylor, JR1
Winkler, G1
Klein, HH; Meier, JJ; Schmidt, WE1
Scheen, AJ1
Amori, RE; Lau, J; Pittas, AG1
Whitehill, D1
Mirza, SA1
Dailey, GE1
Singer, M1
Ahrén, B1
Mikhail, N1
Choe, HM; Sweet, BV; VanDeKoppel, S1
Cohen, AF; Dubois, EA; Pijl, H; van Bronswijk, H1
Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S1
Bunck, MC; Diamant, M1
DeFronzo, RA; Guan, X; Holcombe, JH; MacConell, L; Okerson, T; Viswanathan, P1
Drucker, DJ; Duez, H; Giacca, A; Lewis, GF; Smith, AC; Szeto, L; Xiao, C1
Davidson, JA; Gross, JL; Parente, EB1
Bosi, E; Lucotti, P; Monti, L; Piatti, PM; Setola, E1
Seissler, J1
Egan, JM; Kim, W1
Siddiqui, NI1
Boye, KS; Fabunmi, R; Lage, MJ; Misurski, DA1
Nicolucci, A; Rossi, MC1
Arnold Chan, K; Dore, DD; Seeger, JD1
Gallwitz, B1
Miuchi, M; Miyagawa, J; Nanba, M1
Cognard, E; Shepherd, PR; Smith, GC; Vickers, MH1
Drucker, DJ; Hansotia, T; Longuet, C; Maida, A; Seino, Y1
D'Alessio, D; Jessen, L1
Freeman, JS2
Hoerger, T; Pogach, L; Rajan, M; Sinha, A1
Fontés, G; Hagman, DK; Latour, MG; Poitout, V; Semache, M1
Peters, A1
Bilo, HJ; Goudswaard, AN; Houweling, ST; Kleefstra, N; Kooy, A; van Hateren, KJ; Verhoeven, S1
Berria, R; Davis, KL; Horton, ES; Silberman, C1
Davies, MJ; Engel, SS; Mavros, P; Radican, L; Rajagopalan, S; Yin, D; Zhang, Q1
Guerci, B; Halter, C1
Unger, J1
Kuritzky, L1
Bergenstal, RM; Macconell, L; Malloy, J; Malone, J; Porter, LE; Walsh, B; Wilhelm, K; Wysham, C; Yan, P1
Meier, JJ; Nauck, MA1
Fakhoury, WK; Lereun, C; Wright, D1
Svec, F1
Clar, C; Cummins, E; Marien, M; Philip, S; Richter, B; Royle, P; Waugh, N1
Chen, W; Garg, R; Pendergrass, M1
Borelli, MI; Del Zotto, H; Flores, LE; Francini, F; Gagliardino, JJ; Madrid, VG; Maiztegui, B; Massa, ML; Raschia, MA; Rebolledo, OR1
Garber, AJ1
Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME5
Boudes, P; Viereck, C1
Best, JH; Garrison, LP; Li, Y; Malloy, J; Peyrot, M; Rubin, RR; Yan, P1
Jellinger, PS1
Butler, PC; Elashoff, M; Elashoff, R; Gier, B; Matveyenko, AV1
Spellman, CW1
Bergenstal, R; Malloy, J; Malone, J; Taylor, K; Walsh, B; Wysham, C; Yan, P1
Bourdel-Marchasson, I; Dejager, S; Schweizer, A1
Hawkes, N1
Doggrell, SA1
Avogaro, A; de Kreutzenberg, SV; Fadini, GP; Gjini, R1
Berg, JK; Gray, AL; Heilmann, CR; Holcombe, JH; Shenouda, SK1
Gundert-Remy, U; Spranger, J; Stammschulte, T1
Hurren, KM; Pinelli, NR1
DeYoung, MB; Herbert, P; MacConell, L; Sarin, V; Trautmann, M1
Jermendy, G1
Brubaker, PL; Grieco, A; Iakoubov, R; Lauffer, LM; Sangle, GV; Trivedi, S1
Boardman, MK; Chan, M; Cuddihy, RM; González, JG; Hanefeld, M; Kumar, A; Russell-Jones, D; Wolka, AM1
Chen, W; Fenton, C; Haffner, SM; Pendergrass, M1
Best, JH; DeYoung, MB; Gaebler, JA; Guillermin, AL; Lloyd, A; Samyshkin, Y1
Bachmann, OP; Chan, JY; Lüdemann, J; Oliveira, JH; Reed, VA; Violante, R; Yoon, KH; Yu, MB1
Nauck, MA1
Davies, M; Speight, J1
Ahrén, B; Deacon, CF; Mannucci, E1
Edgerton, LP; Elmore, LK; Patel, MB; Whalin, LM1
Gupta, S1
Ishikawa, M; Yamada, Y1
Buse, J; Jensen, KH; Niswender, K; Pi-Sunyer, X; Russell-Jones, D; Toft, AD; Zinman, B1
Chen, ZY; Huang, Y; Lam, KS; Lau, CW; Liu, J; Liu, L; Ng, CF; Pu, Y; Tian, XY; Wang, YX; Wong, WT; Xu, A; Xu, G; Yao, X; Zhu, Z1
Chen, M; Guo, Z; Hao, J; Houze, J; Lin, DC; Lopez, E; Luo, J; Ma, Z; Nguyen, K; Rulifson, IC; Tian, B; Tian, L; Tran, T; Wang, Y; Zhang, Y1
Hansen, LS; Hare, KJ; Hartmann, B; Holst, JJ; Kissow, H; Poulsen, SS; Rosenkilde, MM; Viby, NE1
Baruah, MP; Chaudhury, T; Dharmalingam, M; Sethi, BK1
Chang, HY; Clark, JM; Richards, TM; Segal, JB; Singh, S; Weiner, JP1
Gale, EA1
Cohen, D1
Grunberger, G1
Hari Kumar, KV; Prusty, P; Shaikh, A1
Drake, AJ; Iyer, SN; Mendez, CE; Tanenberg, RJ; West, RL1
Bergeson, JG; Graham, J; Louder, A; Ward, M; Worley, K1
Han, J; Malloy, J; Meloni, A1
Moniri, NH; Ryan, GJ; Smiley, DD1
Huang, Q; Peng, Y; Wang, Y; Zhao, L1
Harja, E; Lord, J; Skyler, JS1
Chang, CL; Chang, HW; Chang, LT; Chen, HH; Chen, YL; Chen, YT; Leu, S; Sun, CK; Sung, PH; Tsai, TH; Yang, CC; Yip, HK; Zhen, YY1
Cappuccio, F; Ceriello, A; Genovese, S; Schnell, O; Standl, E; Valensi, P1
Anand, S; Bhatia, T; Olaywi, M; Singhal, S1
Gao, Y; Huang, Y; Lau, CW; Liu, J; Liu, L; Ng, CF; Tian, XY; Wong, WT; Xu, A; Xu, G; Yao, X1
Nistala, R; Rao, A1
Rouse, R; Stewart, S; Xu, L; Zhang, J1
Tibaldi, JM1
Duke, J; Li, X; Zhang, Z1
Fuller, CS; Gallop, R; Gudipaty, L; Rickels, MR; Rosenfeld, NK; Schutta, MH1
Kourlaba, G; Maniadakis, N; Melidonis, A; Tzanetakos, C; Verras, C1
Marchesini, G; Melchiorri, D; Montilla, S; Pani, L; Sammarco, A; Siviero, PD; Tomino, C; Trotta, MP1
Ekoé, JM; Kuritzky, L; Landó, LF; Mancillas-Adame, L; Umpierrez, G1
Thompson, AM; Trujillo, JM1
Fukushima, A; Furihata, T; Harashima, S; Homma, T; Kadoguchi, T; Kinugawa, S; Masaki, Y; Matsumoto, J; Matsushima, S; Mizushima, W; Okita, K; Takada, S; Takahashi, M; Tanaka, S; Tsutsui, H; Yokota, T1

Reviews

46 review(s) available for triazoles and exenatide

ArticleYear
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Lancet (London, England), 2006, Nov-11, Volume: 368, Issue:9548

    Topics: Adamantane; Adenosine Deaminase Inhibitors; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin

2006
Diabetes drug update: how 4 new options stack up.
    The Journal of family practice, 2007, Volume: 56, Issue:3

    Topics: Administration, Inhalation; Amyloid; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Exenatide; Family Practice; Female; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Islet Amyloid Polypeptide; Male; Peptides; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms

2007
[Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
    Orvosi hetilap, 2007, Apr-01, Volume: 148, Issue:13

    Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Insulin Resistance; Intestinal Mucosa; Nitriles; Peptide Hormones; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin

2007
[New concepts in the treatment of type 2 diabetes].
    Der Internist, 2007, Volume: 48, Issue:7

    Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Nitriles; Peptides; Piperidines; Pyrazines; Pyrazoles; Pyrrolidines; Rimonabant; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin

2007
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
    JAMA, 2007, Jul-11, Volume: 298, Issue:2

    Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin

2007
Using prandial insulin to achieve glycemic control in type 2 diabetes.
    The Journal of family practice, 2007, Volume: 56, Issue:9

    Topics: Algorithms; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Peptides; Postprandial Period; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms

2007
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
    Current diabetes reports, 2007, Volume: 7, Issue:5

    Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Exenatide; Gastric Emptying; Glucagon-Like Peptide 1; Hypoglycemic Agents; Incretins; Islets of Langerhans; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin

2007
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Expert opinion on investigational drugs, 2008, Volume: 17, Issue:6

    Topics: Adamantane; Body Weight; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nausea; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Vomiting

2008
Managed care perspective on three new agents for type 2 diabetes.
    Journal of managed care pharmacy : JMCP, 2008, Volume: 14, Issue:4

    Topics: Amyloid; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Managed Care Programs; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms

2008
[New drugs; exenatide and sitagliptin].
    Nederlands tijdschrift voor geneeskunde, 2008, Apr-12, Volume: 152, Issue:15

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Exenatide; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms

2008
Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
    Current opinion in clinical nutrition and metabolic care, 2008, Volume: 11, Issue:4

    Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin

2008
Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
    Arquivos brasileiros de endocrinologia e metabologia, 2008, Volume: 52, Issue:6

    Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Postprandial Period; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin

2008
Incretin-based therapies in type 2 diabetes: a review of clinical results.
    Diabetes research and clinical practice, 2008, Dec-15, Volume: 82 Suppl 2

    Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin

2008
The role of incretins in glucose homeostasis and diabetes treatment.
    Pharmacological reviews, 2008, Volume: 60, Issue:4

    Topics: Animals; Diabetes Mellitus; Exenatide; Glucose; Homeostasis; Humans; Hypoglycemic Agents; Incretins; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms

2008
Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Mymensingh medical journal : MMJ, 2009, Volume: 18, Issue:1

    Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin

2009
Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.
    Acta bio-medica : Atenei Parmensis, 2008, Volume: 79, Issue:3

    Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin

2008
[The value of incretin based therapies].
    Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:20

    Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin

2009
[Incretin related agents for treatment of diabetes mellitus].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2009, Apr-10, Volume: 98, Issue:4

    Topics: Adamantane; Diabetes Mellitus; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin

2009
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Cleveland Clinic journal of medicine, 2009, Volume: 76 Suppl 5

    Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glutaminase; Homeostasis; Humans; Hypoglycemic Agents; Incretins; Intracellular Signaling Peptides and Proteins; Peptides; Pyrazines; Signal Transduction; Sitagliptin Phosphate; Triazoles; Venoms

2009
Incretin-based therapies: review of current clinical trial data.
    The American journal of medicine, 2010, Volume: 123, Issue:3 Suppl

    Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms

2010
[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
    Nederlands tijdschrift voor geneeskunde, 2010, Volume: 154

    Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin

2010
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
    The American journal of the medical sciences, 2010, Volume: 340, Issue:2

    Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Patient Compliance; Peptides; Piperidines; Precision Medicine; Primary Health Care; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin

2010
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
    Pharmacology, 2010, Volume: 86, Issue:1

    Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Weight Loss

2010
Incretin physiology and its role in type 2 diabetes mellitus.
    The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:7 Suppl 7

    Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms

2010
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2010, Volume: 14, Issue:36

    Topics: Adamantane; Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Nitriles; Peptides; Pyrazines; Pyrrolidines; Quality of Life; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; State Medicine; Thiazolidinediones; Triazoles; United Kingdom; Venoms; Vildagliptin

2010
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
    The American journal of managed care, 2010, Volume: 16, Issue:7 Suppl

    Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Liraglutide; Managed Care Programs; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms

2010
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Postgraduate medicine, 2011, Volume: 123, Issue:1

    Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms

2011
Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients.
    The Journal of the American Osteopathic Association, 2011, Volume: 111, Issue:2 Suppl 1

    Topics: Algorithms; Chronic Disease; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms

2011
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
    Hospital practice (1995), 2011, Volume: 39, Issue:1

    Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin

2011
Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:13

    Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Humans; Hypoglycemic Agents; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms

2011
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    The Annals of pharmacotherapy, 2011, Volume: 45, Issue:7-8

    Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms

2011
Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
    Diabetes technology & therapeutics, 2011, Volume: 13, Issue:11

    Topics: Adult; Blood Glucose; Capsules; Diabetes Mellitus, Type 2; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Lactic Acid; Peptides; Pioglitazone; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms

2011
[Incretin-based therapy for treating patients with type 2 diabetes].
    Orvosi hetilap, 2011, Nov-27, Volume: 152, Issue:48

    Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin

2011
The design of the liraglutide clinical trial programme.
    Diabetes, obesity & metabolism, 2012, Volume: 14 Suppl 2

    Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms

2012
Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:10

    Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Liraglutide; Male; Medication Adherence; Patient Satisfaction; Peptides; Pyrazines; Self Care; Sitagliptin Phosphate; Surveys and Questionnaires; Treatment Outcome; Triazoles; Venoms; Weight Loss

2012
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:8

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Liraglutide; Male; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms

2012
Immunotherapies in diabetes mellitus type 1.
    The Medical clinics of North America, 2012, Volume: 96, Issue:3

    Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Azathioprine; Basiliximab; Chaperonin 60; Cyclosporine; Daclizumab; Diabetes Mellitus, Type 1; Diet; Etanercept; Exenatide; Fatty Acids, Unsaturated; Glutamate Decarboxylase; Humans; Hypoglycemic Agents; Immunoconjugates; Immunoglobulin G; Immunosuppressive Agents; Insulin; Interferon-alpha; Interleukin 1 Receptor Antagonist Protein; Islets of Langerhans Transplantation; Niacinamide; Peptide Fragments; Peptides; Primary Prevention; Pyrazines; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Rituximab; Secondary Prevention; Sitagliptin Phosphate; Tertiary Prevention; Triazoles; Venoms; Vitamin D; Vitamins

2012
Liraglutide in type 2 diabetes mellitus.
    Journal of the Indian Medical Association, 2012, Volume: 110, Issue:5

    Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms

2012
Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
    Journal of diabetes, 2013, Volume: 5, Issue:3

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Molecular Structure; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms

2013
Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, Jul-01, Volume: 70, Issue:13

    Topics: Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Evidence-Based Medicine; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms

2013
Type 1 diabetes and cardiovascular disease.
    Cardiovascular diabetology, 2013, Oct-28, Volume: 12

    Topics: Antihypertensive Agents; Autonomic Nervous System Diseases; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diabetic Neuropathies; Drug Therapy, Combination; Exenatide; Exercise Therapy; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Insulin; Oxidative Stress; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms

2013
Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2013, Volume: 12, Issue:6

    Topics: Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fatty Liver; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Liver; Non-alcoholic Fatty Liver Disease; Peptides; Pyrazines; Sitagliptin Phosphate; Transaminases; Treatment Outcome; Triazoles; Venoms

2013
Is there a role for the incretin system in blood pressure regulation?
    Current hypertension reports, 2014, Volume: 16, Issue:3

    Topics: Animals; Blood Pressure; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypertension; Incretins; Oxidative Stress; Peptides; Pyrazines; Renin-Angiotensin System; Sitagliptin Phosphate; T-Lymphocytes, Regulatory; Triazoles; Venoms

2014
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
    Advances in therapy, 2014, Volume: 31, Issue:3

    Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss

2014
Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.
    Postgraduate medicine, 2014, Volume: 126, Issue:6

    Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms

2014
Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
    The Annals of pharmacotherapy, 2015, Volume: 49, Issue:3

    Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms

2015

Trials

12 trial(s) available for triazoles and exenatide

ArticleYear
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
    Current medical research and opinion, 2008, Volume: 24, Issue:10

    Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake; Exenatide; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Peptides; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Stomach; Triazoles; Venoms

2008
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
    Lancet (London, England), 2010, Aug-07, Volume: 376, Issue:9739

    Topics: Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Computer-Assisted; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipid A; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms

2010
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.
    Diabetes care, 2011, Volume: 34, Issue:2

    Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Female; Health Status; Humans; Hypoglycemic Agents; Male; Mental Health; Middle Aged; Patient Satisfaction; Peptides; Pioglitazone; Pyrazines; Quality of Life; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms

2011
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:6

    Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms

2011
The metabolic syndrome influences the response to incretin-based therapies.
    Acta diabetologica, 2011, Volume: 48, Issue:3

    Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Male; Metabolic Syndrome; Middle Aged; Nitriles; Peptides; Prognosis; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin

2011
Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:11

    Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Peptides; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms; Young Adult

2011
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
    Diabetes care, 2012, Volume: 35, Issue:2

    Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms

2012
A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitaglipti
    Diabetic medicine : a journal of the British Diabetic Association, 2012, Volume: 29, Issue:11

    Topics: Adolescent; Adult; Aged; Argentina; Australia; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Germany; Glycated Hemoglobin; Greece; Humans; Hypoglycemia; Hypoglycemic Agents; India; Male; Metformin; Mexico; Middle Aged; Peptides; Pyrazines; Republic of Korea; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms

2012
Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:1

    Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Weight Loss

2013
Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
    Diabetes research and clinical practice, 2013, Volume: 100, Issue:2

    Topics: Adult; Diabetes Mellitus, Type 1; Exenatide; Female; Humans; Insulin; Male; Peptides; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Young Adult

2013
Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
    Postgraduate medicine, 2013, Volume: 125, Issue:3

    Topics: Blood Glucose; Body Weight; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms

2013
Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.
    Diabetes care, 2014, Volume: 37, Issue:9

    Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Peptides; Prognosis; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; Venoms; Young Adult

2014

Other Studies

59 other study(ies) available for triazoles and exenatide

ArticleYear
[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
    Revue medicale de Liege, 2007, Volume: 62, Issue:4

    Topics: Adamantane; Animals; Appetite; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin

2007
[New class of oral antidiabetic drugs. Effective in combination with metformin].
    MMW Fortschritte der Medizin, 2007, Volume: 149, Issue:1-2

    Topics: Administration, Oral; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms

2007
Treatment of type 2 diabetes mellitus and the incretin system.
    South Dakota medicine : the journal of the South Dakota State Medical Association, 2007, Volume: 60, Issue:5

    Topics: Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; United States; Venoms

2007
New medications help those with diabetes avoid heart trouble. Drugs mimic the body's natural insulin and glucose controls, but diet and exercise are still keys to controlling the disease.
    Heart advisor, 2007, Volume: 10, Issue:7

    Topics: Diabetes Mellitus; Diabetic Angiopathies; Exenatide; Heart Diseases; Humans; Hypoglycemic Agents; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms

2007
Type 2 diabetes drug boom: is newer better?
    The Johns Hopkins medical letter health after 50, 2007, Volume: 19, Issue:6

    Topics: Amyloid; Diabetes Mellitus; Exenatide; Humans; Hypoglycemic Agents; Insulin; Islet Amyloid Polypeptide; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms

2007
Type 2 diabetes: the end of clinical inertia.
    Southern medical journal, 2007, Volume: 100, Issue:8

    Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Nebulizers and Vaporizers; Peptides; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms

2007
Management of comorbid diabetes and cancer.
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:8 Suppl

    Topics: Ambulatory Care; Amyloid; Comorbidity; Diabetes Mellitus; Exenatide; Humans; Hypoglycemic Agents; Inpatients; Insulin; Islet Amyloid Polypeptide; Neoplasms; Peptides; Practice Guidelines as Topic; Pyrazines; Quality of Life; Risk Factors; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms

2007
Three new drugs for type 2 diabetes.
    Drug and therapeutics bulletin, 2008, Volume: 46, Issue:7

    Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin

2008
[New drugs; exenatide and sitagliptin].
    Nederlands tijdschrift voor geneeskunde, 2008, Jul-26, Volume: 152, Issue:30

    Topics: Exenatide; Glucagon-Like Peptide 1; Humans; Insulin; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms

2008
Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.
    Endocrinology, 2009, Volume: 150, Issue:1

    Topics: Animals; Blood Glucose; Body Weight; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucose Clamp Technique; Glucose Tolerance Test; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Mice; Mice, Inbred C57BL; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms

2009
[Future therapeutic options and their indications: transplantation and the possibilities of regenerative therapy for diabetes type 1].
    MMW Fortschritte der Medizin, 2008, Oct-30, Volume: 150, Issue:44

    Topics: Adamantane; Animals; Diabetes Mellitus, Type 1; Exenatide; Humans; Insulin-Secreting Cells; Islets of Langerhans; Islets of Langerhans Transplantation; Mice; Nitriles; Peptides; Pyrazines; Pyrrolidines; Regeneration; Sitagliptin Phosphate; Stem Cell Transplantation; Transplantation, Heterologous; Triazoles; Venoms; Vildagliptin

2008
Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.
    Advances in therapy, 2009, Volume: 26, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Cost Savings; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Costs; Emergency Service, Hospital; Exenatide; Female; Glycated Hemoglobin; Health Care Costs; Health Services Research; Humans; Hypoglycemic Agents; Insurance Claim Review; Male; Middle Aged; Multivariate Analysis; Peptides; Pyrazines; Regression Analysis; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States; Venoms

2009
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.
    Current medical research and opinion, 2009, Volume: 25, Issue:4

    Topics: Adolescent; Adult; Databases, Factual; Exenatide; Female; Glyburide; Humans; Hypoglycemic Agents; Insurance, Health; Male; Metformin; Middle Aged; Pancreatitis; Peptides; Pyrazines; Risk Assessment; Safety; Sitagliptin Phosphate; Triazoles; United States; Venoms; Young Adult

2009
Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour.
    Schizophrenia research, 2009, Volume: 115, Issue:1

    Topics: Analysis of Variance; Animals; Antipsychotic Agents; Body Composition; Body Weight; Clozapine; Dibenzothiazepines; Dietary Fats; Disease Models, Animal; Eating; Exenatide; Food Preferences; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Male; Obesity; Peptides; Pyrazines; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles; Venoms

2009
Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
    Gastroenterology, 2009, Volume: 137, Issue:6

    Topics: Animals; Apoptosis; Blood Glucose; Caspase 3; Cell Line; Cell Proliferation; Cell Survival; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Hypoglycemic Agents; Incretins; Insulin; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Peptides; Pyrazines; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Signal Transduction; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms

2009
[Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].
    MMW Fortschritte der Medizin, 2009, May-07, Volume: 151, Issue:19

    Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucose; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Weight Loss

2009
The incretins and beta-cell health: contrasting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 as a path to understand islet function in diabetes.
    Gastroenterology, 2009, Volume: 137, Issue:6

    Topics: Animals; Blood Glucose; Cell Proliferation; Cell Survival; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin-Secreting Cells; Mice; Peptides; Pyrazines; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Signal Transduction; Sitagliptin Phosphate; Triazoles; Venoms

2009
Costs and consequences associated with newer medications for glycemic control in type 2 diabetes.
    Diabetes care, 2010, Volume: 33, Issue:4

    Topics: Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Peptides; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Triazoles; Venoms

2010
Lack of preservation of insulin gene expression by a glucagon-like peptide 1 agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model of glucolipotoxicity.
    Diabetes research and clinical practice, 2010, Volume: 87, Issue:3

    Topics: Analysis of Variance; Animals; Blood Glucose; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Eating; Exenatide; Fat Emulsions, Intravenous; Gene Expression; Glucagon-Like Peptide 1; Glucose; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Lipids; Male; Peptides; Pyrazines; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sitagliptin Phosphate; Triazoles; Venoms

2010
New therapeutic options: management strategies to optimize glycemic control.
    The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:3 Suppl 2

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Life Style; Male; Metformin; Middle Aged; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms

2010
Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.
    Diabetes care, 2010, Volume: 33, Issue:8

    Topics: Aged; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Multivariate Analysis; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss

2010
Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
    Advances in therapy, 2010, Volume: 27, Issue:4

    Topics: Adult; Age Factors; Aged; Body Mass Index; Body Weight; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insurance Claim Review; Lipids; Male; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Sex Factors; Sitagliptin Phosphate; Socioeconomic Factors; Triazoles; Venoms

2010
[New hypoglycemic agents in type 2 diabetes].
    La Revue du praticien, 2010, Apr-20, Volume: 60, Issue:4

    Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin

2010
Choosing among the incretin agents and why it matters.
    The Journal of family practice, 2010, Volume: 59, Issue:5 Suppl

    Topics: Adamantane; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Lipids; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss

2010
Individualised incretin-based treatment for type 2 diabetes.
    Lancet (London, England), 2010, Aug-07, Volume: 376, Issue:9739

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms

2010
Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.
    Diabetes care, 2010, Volume: 33, Issue:11

    Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pancreatitis; Peptides; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Venoms

2010
Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats.
    Clinical science (London, England : 1979), 2011, Volume: 120, Issue:2

    Topics: Animals; Apoptosis; Blood Glucose; Body Weight; Diet; Dipeptidyl-Peptidase IV Inhibitors; Drinking; Drug Evaluation, Preclinical; Eating; Exenatide; Fatty Liver; Fructose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metabolic Syndrome; Peptides; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Venoms

2011
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
    The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1

    Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms

2010
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
    The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1

    Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss

2010
Distinguishing among incretin-based therapies. Patient education and self-management.
    The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1

    Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms

2010
Distinguishing among incretin-based therapies. Introduction.
    The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1

    Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liraglutide; Metformin; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms

2010
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
    The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1

    Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms

2010
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
    Contemporary clinical trials, 2011, Volume: 32, Issue:3

    Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin

2011
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
    Gastroenterology, 2011, Volume: 141, Issue:1

    Topics: Adverse Drug Reaction Reporting Systems; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Odds Ratio; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Thyroid Neoplasms; Triazoles; United States; United States Food and Drug Administration; Venoms

2011
Journal withdraws article after complaints from drug manufacturers.
    BMJ (Clinical research ed.), 2011, Apr-11, Volume: 342

    Topics: Diabetes Mellitus, Type 2; Drug Industry; Editorial Policies; Exenatide; Humans; Hypoglycemic Agents; Incretins; Pancreatitis; Peptides; Periodicals as Topic; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms

2011
GLP-1-based therapies: the dilemma of uncertainty.
    Gastroenterology, 2011, Volume: 141, Issue:1

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Thyroid Neoplasms; Triazoles; Uncertainty; Venoms

2011
Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise.
    Prescrire international, 2011, Volume: 20, Issue:121

    Topics: Exenatide; Humans; Hypoglycemic Agents; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms

2011
Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.
    Endocrinology, 2012, Volume: 153, Issue:2

    Topics: Animals; Animals, Newborn; Cell Line; Cyclic AMP; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Exenatide; Extracellular Signal-Regulated MAP Kinases; Glucagon-Like Peptide 1; Humans; Ionomycin; Mice; Molecular Structure; Peptides; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Venoms

2012
Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:7

    Topics: Acute Kidney Injury; Adolescent; Adult; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Labeling; Exenatide; Female; Humans; Incidence; Male; Middle Aged; Peptides; Proportional Hazards Models; Pyrazines; Retrospective Studies; Risk Assessment; Sitagliptin Phosphate; Triazoles; Venoms; Young Adult

2012
Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
    Journal of medical economics, 2012, Volume: 15, Issue:4

    Topics: Adult; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Humans; Hypoglycemic Agents; Long-Term Care; Male; Markov Chains; Middle Aged; Models, Theoretical; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; United States; Venoms

2012
Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2012, Jun-15, Volume: 69, Issue:12

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms

2012
[Therapeutic use and adverse events of incretin-related drugs].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 3

    Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin

2012
Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
    Hypertension (Dallas, Tex. : 1979), 2012, Volume: 60, Issue:3

    Topics: Aged; Aged, 80 and over; Animals; Blood Pressure; Cells, Cultured; Cyclic AMP; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Endothelium, Vascular; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypertension; In Vitro Techniques; Kidney; Magnetic Resonance Imaging; Male; Middle Aged; Nitric Oxide; Peptides; Pyrazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Glucagon; Regional Blood Flow; Renal Artery; Signal Transduction; Sitagliptin Phosphate; Triazoles; Venoms

2012
Evaluating insulin secretagogues in a humanized mouse model with functional human islets.
    Metabolism: clinical and experimental, 2013, Volume: 62, Issue:1

    Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glyburide; Humans; Incretins; Insulin; Insulin Secretion; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Mice; Mice, Nude; Nateglinide; Peptides; Phenylalanine; Pyrazines; Sitagliptin Phosphate; Specific Pathogen-Free Organisms; Triazoles; Venoms

2013
Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Regulatory peptides, 2012, Nov-10, Volume: 179, Issue:1-3

    Topics: 1,2-Dimethylhydrazine; Aberrant Crypt Foci; Adenoma; Anatomy, Cross-Sectional; Animals; Chlorocebus aethiops; Colon; Colonic Neoplasms; COS Cells; Cyclic AMP; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptide-2 Receptor; Hypoglycemic Agents; Intestinal Mucosa; Intestine, Small; Liraglutide; Mice; Mice, Inbred C57BL; Organ Size; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Transfection; Triazoles; Venoms

2012
Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
    JAMA internal medicine, 2013, Apr-08, Volume: 173, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Hospitalization; Humans; Logistic Models; Male; Middle Aged; Pancreatitis; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms

2013
GLP-1 based agents and acute pancreatitis : drug safety falls victim to the three monkey paradigm.
    BMJ (Clinical research ed.), 2013, Feb-27, Volume: 346

    Topics: Acute Disease; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Metaphor; Pancreatitis; Peptides; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms

2013
Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows.
    BMJ (Clinical research ed.), 2013, Feb-27, Volume: 346

    Topics: Acute Disease; Animals; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Exenatide; Humans; Hypoglycemic Agents; Pancreatitis; Peptides; Pyrazines; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms

2013
Pancreatitis associated with incretin-based therapies.
    Diabetes care, 2013, Volume: 36, Issue:4

    Topics: Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Incretins; Pancreatitis; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms

2013
Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
    Journal of managed care pharmacy : JMCP, 2013, Volume: 19, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Exenatide; Female; Health Care Costs; Humans; Hypoglycemic Agents; Linear Models; Male; Medicare Part D; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States; Venoms; Young Adult

2013
Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
    Journal of diabetes, 2014, Volume: 6, Issue:2

    Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Fasting; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Metformin; Middle Aged; Peptides; Piperidines; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Failure; Triazoles; Venoms

2014
An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.
    Diabetes technology & therapeutics, 2013, Volume: 15, Issue:8

    Topics: Adolescent; Adult; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hyperplasia; Hypoglycemic Agents; Incretins; Male; Middle Aged; Models, Statistical; Pancreas; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Tissue Banks; Triazoles; Venoms; Young Adult

2013
Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction.
    Journal of translational medicine, 2013, Oct-25, Volume: 11

    Topics: Animals; Biomarkers; Creatinine; Exenatide; Inflammation; Kidney; Male; Oxidative Stress; Peptides; Proteinuria; Pyrazines; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reperfusion Injury; Sitagliptin Phosphate; Triazoles; Venoms

2013
Uncoupling protein-2 mediates DPP-4 inhibitor-induced restoration of endothelial function in hypertension through reducing oxidative stress.
    Antioxidants & redox signaling, 2014, Oct-10, Volume: 21, Issue:11

    Topics: Animals; Cyclooxygenase 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Endothelium, Vascular; Exenatide; Gene Expression Regulation; Humans; Hypertension; Ion Channels; Male; Mice; Mitochondria; Mitochondrial Proteins; Models, Biological; Oxidative Stress; Peptides; Pyrazines; Rats; Rats, Inbred SHR; Reactive Oxygen Species; Renal Artery; Sitagliptin Phosphate; Triazoles; Uncoupling Protein 2; Vasoconstriction; Venoms

2014
High fat diet and GLP-1 drugs induce pancreatic injury in mice.
    Toxicology and applied pharmacology, 2014, Apr-15, Volume: 276, Issue:2

    Topics: Acute Disease; Animals; Apoptosis; Atrophy; Diet, High-Fat; Exenatide; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Necrosis; Pancreas; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms

2014
Glucagon-like peptide 1-based therapies and risk of pancreatitis: a self-controlled case series analysis.
    Pharmacoepidemiology and drug safety, 2014, Volume: 23, Issue:3

    Topics: Adult; Aged; Cohort Studies; Databases, Factual; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Pancreatitis; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms; Young Adult

2014
Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.
    BMC health services research, 2014, Sep-22, Volume: 14

    Topics: Adult; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide 1; Greece; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms

2014
Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2014, Volume: 24, Issue:12

    Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Monitoring, Physiologic; Nitriles; Peptides; Pyrazines; Pyrrolidines; Registries; Sex Factors; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin

2014
Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling.
    Cardiovascular research, 2016, Volume: 111, Issue:4

    Topics: Animals; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Male; Mice, Inbred C57BL; Mitochondria; Muscle, Skeletal; Myocardial Infarction; Organelle Biogenesis; Peptides; Triazoles; Venoms

2016